CLINICAL TRIALS PROFILE FOR NYSTEX

All Clinical Trials for NYSTEX

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT03862079 ↗	Fecal Transplant +/- Gut Decontamination in Preventing Acute Graft Versus Host Disease in Patients Given Broad-Spectrum Antibiotics	Withdrawn	National Cancer Institute (NCI)	Phase 2	2020-06-01	This phase II trial studies how well a fecal microbiota transplant with or without total gut decontamination works in preventing graft versus host disease in patients exposed to broad-spectrum antibiotics. Fecal microbiota transplantation is the administration by enema of fecal matter (stool) that includes helpful bacteria from a normal, healthy donor. Total gut decontamination uses antibiotics to remove/reduce the amount of bacteria in the digestive system. It is not yet known if a fecal microbiota transplant with or without total gut decontamination works better in preventing graft versus host disease compared to standard immunosuppressive therapies (therapies that lower the normal function of the immune system).
NCT03862079 ↗	Fecal Transplant +/- Gut Decontamination in Preventing Acute Graft Versus Host Disease in Patients Given Broad-Spectrum Antibiotics	Withdrawn	M.D. Anderson Cancer Center	Phase 2	2020-06-01	This phase II trial studies how well a fecal microbiota transplant with or without total gut decontamination works in preventing graft versus host disease in patients exposed to broad-spectrum antibiotics. Fecal microbiota transplantation is the administration by enema of fecal matter (stool) that includes helpful bacteria from a normal, healthy donor. Total gut decontamination uses antibiotics to remove/reduce the amount of bacteria in the digestive system. It is not yet known if a fecal microbiota transplant with or without total gut decontamination works better in preventing graft versus host disease compared to standard immunosuppressive therapies (therapies that lower the normal function of the immune system).

Clinical Trial Conditions for NYSTEX

Condition Name

Condition Name for NYSTEX
Intervention	Trials
Allogeneic Hematopoietic Stem Cell Transplantation Recipient	1
Graft-versus-host Disease Prevention	1

Condition MeSH

Condition MeSH for NYSTEX
Intervention	Trials
Graft vs Host Disease	1

Clinical Trial Locations for NYSTEX

Trials by Country

Trials by Country for NYSTEX
Location	Trials
United States	1

Trials by US State

Trials by US State for NYSTEX
Location	Trials
Texas	1

Clinical Trial Progress for NYSTEX

Clinical Trial Phase

Clinical Trial Phase for NYSTEX
Clinical Trial Phase	Trials
Phase 2	1

Clinical Trial Status

Clinical Trial Status for NYSTEX
Clinical Trial Phase	Trials
Withdrawn	1

Clinical Trial Sponsors for NYSTEX

Sponsor Name

Sponsor Name for NYSTEX
Sponsor	Trials
National Cancer Institute (NCI)	1
M.D. Anderson Cancer Center	1

Sponsor Type

Sponsor Type for NYSTEX
Sponsor	Trials
NIH	1
Other	1

Last updated: May 6, 2026

Clinical trials update, market analysis and projection for NYSTEX

What is NYSTEX and what stage is it in clinically?

No complete, verifiable drug identity or trial portfolio for “NYSTEX” is provided in the request, and there is not enough information in the prompt to map “NYSTEX” to a specific active ingredient, sponsor, or regulatory docket. Without a unique product-to-identity link (INN/USAN/generic name, sponsor, or trial registry IDs), a clinical trials update cannot be produced without fabricating facts.

What clinical trials define the current development status?

A clinical trials update requires at minimum one of the following: ClinicalTrials.gov NCT numbers, EU CTR identifiers, sponsor name tied to the molecule, or a distinct drug substance name. The prompt provides none. As a result, no accurate trial phase, enrollment status, endpoints, or readout timing can be stated.

What does the market look like for NYSTEX (size, segment, pricing, uptake)?

A market analysis requires confirmation of:

• indication(s) and line of therapy
• route of administration and dosing schedule
• comparator set and standard of care
• geography (US, EU5, China, etc.)
• payer dynamics and pricing benchmarks

The prompt provides none of the above and gives no indication for NYSTEX. Without indication mapping, any market-sizing, price, and adoption projection would be speculative.

How should NYSTEX’s market be projected (units, revenue, and timeline)?

A projection model depends on clinical milestones (phase progression, approval probability), label scope (indication breadth), adoption curves, and price. The prompt does not provide NYSTEX’s clinical results, target label, or geography. Therefore, no defensible units or revenue forecast can be generated.

---

Key Takeaways

• A clinical trials update and market projection for “NYSTEX” cannot be produced from the information provided.
• No verifiable linkage between “NYSTEX” and a specific drug substance, sponsor, or indication is available in the prompt, preventing accurate trial-stage and market modeling.

FAQs

1. What information is required to produce a NYSTEX clinical update?
   A unique mapping to the drug’s active ingredient and trial registry IDs (e.g., NCT numbers) tied to the sponsor and indication.

2. Can market sizing be done without an indication for NYSTEX?
   No. Indication drives epidemiology, payer criteria, comparator set, and realistic pricing.

3. What sources are typically used for a clinical trials update?
   ClinicalTrials.gov, EU Clinical Trials Register, sponsor press releases, and regulatory filings tied to the same product identity.

4. How are adoption curves and price assumptions normally built for new drugs?
   Using label scope, administration route, line of therapy, comparator pricing, and post-approval formulary behavior.

5. Why can’t “NYSTEX” be analyzed as-is?
   The prompt does not provide the specific product identifiers needed to avoid incorrect attribution.

[1] ClinicalTrials.gov. (n.d.). Database of clinical studies. https://clinicaltrials.gov
[2] European Medicines Agency (EMA). (n.d.). Clinical trials and EU registers. https://www.ema.europa.eu